Pulmonary Therapeutic Formulation for Rapid and Consistent Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic agents administered orally face inconsistent absorption, low bioavailability, and delayed onset of action, making it difficult to assess drug effects and determine additional doses, particularly for drugs like melatonin and nicotine.
Innovation Solution
A therapeutic formulation for pulmonary or sublingual delivery using a metered dose inhaler, comprising a therapeutically effective amount of an active agent, a propellant, and a co-solvent, which allows for rapid drug effects and improved bioavailability, enabling users to administer drugs like melatonin and nicotine more effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration is used, then the drug can be easily administered, but the absorption is inconsistent and bioavailability is low
Solution Approach 1:
The patent changes the administration route parameter from oral to pulmonary inhalation, fundamentally altering how the drug is delivered to the body. This parameter change enables direct deposition of the active agent onto the mucous membrane of the respiratory tract, bypassing the inconsistent absorption issues of oral administration while maintaining ease of use through simple inhalation.
Solution Approach 2:
The patent introduces a propellant as an intermediary substance that facilitates the delivery of the active agent to the target site. The propellant forms an aerosol solution with the active agent, enabling it to be delivered efficiently through the inhalation device and absorbed rapidly by the respiratory mucous membrane, thus improving both absorption consistency and ease of administration.
2Ease of operation
If oral administration is used, then the drug can be administered simply, but the onset of action is delayed
Solution Approach 1:
The patent changes the delivery parameter from oral to pulmonary, which fundamentally alters the absorption timeline. Pulmonary delivery bypasses the digestive system and directly deposits the active agent onto the respiratory mucous membrane, reducing the onset of action from 20-60 minutes to approximately 5-10 minutes while maintaining simple administration through inhalation.
Solution Approach 2:
The patent employs preliminary action by pre-formulating the active agent in an aerosol solution with the propellant before administration. This pre-prepared aerosol formulation ensures that the active agent is already in a state optimized for rapid absorption, eliminating the need for dissolution or breakdown processes that occur with oral tablets, thus reducing the onset of action time.
3Ease of manufacture
If oral administration is used, then the drug can be taken as a tablet, but the bioavailability is very low
Solution Approach 1:
The patent changes the formulation parameter from solid tablet to aerosol solution, fundamentally altering the bioavailability profile. The aerosol formulation delivers the active agent in a fine particulate form that directly contacts the respiratory mucous membrane, achieving 10-200 times greater bioavailability compared to oral tablets while maintaining ease of manufacture through standard aerosol formulation techniques.
Solution Approach 2:
The patent introduces the propellant as an intermediary that enables the active agent to be delivered in an aerosol form, which is then absorbed by the respiratory mucous membrane. This intermediary propellant system achieves 10-200 times greater bioavailability compared to direct tablet administration, while the formulation can still be manufactured using conventional aerosol filling techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides rapid drug effects, enhancing user compliance by allowing immediate assessment of dosage needs and reducing overdosing, with bioavailability 10-200 times greater than nasal and gastrointestinal routes.
Implementation Method 1
The therapeutic formulation includes a propellant and a co-solvent, which allows for rapid drug effects and improved bioavailability
Implementation Method 2
A therapeutic formulation for pulmonary or sublingual delivery using a metered dose inhaler
Data Source
AI summary
Ingestion of therapeutic agents are characterized by low bioavailability, a lengthy onset of action, and inconsistent absorption. A therapeutic formulation for pulmonary or sublingual administration of an active agent is disclosed. The therapeutic formulation includes an active agent that can be absorbed through the pulmonary membrane or sublingual tissues for rapid absorption and high bioavailability. In particular examples, the active agent includes nicotine or melatonin. The therapeutic formulation further includes a co-solvent and a propellant.